Xiaolin Dong

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Dalong Zhu, Shenglian Gan, Yu Liu et al. · The Lancet Diabetes & Endocrinology · 2018 · 97 citations

Dorzagliatin Monotherapy, Diabetes Management, Medicine +7

Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in <scp>SUSTAIN China</scp> : A 30‐week, double‐blind, phase 3a, randomized trial

Linong Ji, Xiaolin Dong, Yiming Li et al. · Diabetes Obesity and Metabolism · 2020 · 92 citations · Full text

Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Dalong Zhu, Jianhua Ma, Jiao’e Zeng et al. · Nature Medicine · 2022 · 87 citations · Full text

Metabolic Syndrome, Diabetes Management, Placebo-controlled Phase 3 +8

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Wenying Yang, Dalong Zhu, Shenglian Gan et al. · Nature Medicine · 2022 · 73 citations · Full text

Metabolic Syndrome, Adverse Events, Diabetes Management +10

Efficiency of anthropometric indicators of obesity for identifying cardiovascular risk factors in a Chinese population

Xiaolin Dong, Yang Liu, Jie Yang et al. · Postgraduate Medical Journal · 2011 · 53 citations